Galapagos Partners with Blood Centers of America to Decentralize CAR-T Production

Published: May 16, 2024 By Tristan Manalac

IV bag_iStock, Sergey Mikheev

Pictured: Healthcare worker carrying an IV bag/iStock, Sergey Mikheev

Belgian biotech Galapagos announced on Wednesday that it is enlisting Blood Centers of America in its strategic goal of decentralizing the manufacturing of CAR-T cell therapeutics in the United States.

The partners did not disclose the specific financial details of the deal but said it would give Galapagos access to Blood Centers of America’s (BCA) more than 50 community blood centers across 43 states, enabling the biotech to manufacture its CAR-T cancer therapies closer to treatment centers.

The agreement will also allow Galapagos to deploy its decentralized CAR-T manufacturing platform in the U.S., with the ability to deliver “fresh, fit cells with a vein-to-vein time of seven days,” according to the announcement.

Galapagos CEO Paul Stoffels in a statement…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks